De-Differentiation Confers Multidrug Resistance Via Noncanonical PERK-Nrf2 Signaling
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Malignant carcinomas that recur following therapy are typically de-differentiated and multidrug resistant (MDR). De-differentiated cancer cells acquire MDR by up-regulating reactive oxygen species (ROS)-scavenging enzymes and drug efflux pumps, but how these genes are up-regulated in response to de-differentiation is not known. Here, we examine this question by using global transcriptional profiling to identify ROS-induced genes that are already up-regulated in de-differentiated cells, even in the absence of oxidative damage. Using this approach, we found that the Nrf2 transcription factor, which is the master regulator of cellular responses to oxidative stress, is preactivated in de-differentiated cells. In de-differentiated cells, Nrf2 is not activated by oxidation but rather through a noncanonical mechanism involving its phosphorylation by the ER membrane kinase PERK. In contrast, differentiated cells require oxidative damage to activate Nrf2. Constitutive PERK-Nrf2 signaling protects de-differentiated cells from chemotherapy by reducing ROS levels and increasing drug efflux. These findings are validated in therapy-resistant basal breast cancer cell lines and animal models, where inhibition of the PERK-Nrf2 signaling axis reversed the MDR of de-differentiated cancer cells. Additionally, analysis of patient tumor datasets showed that a PERK pathway signature correlates strongly with chemotherapy resistance, tumor grade, and overall survival. Collectively, these results indicate that de-differentiated cells up-regulate MDR genes via PERK-Nrf2 signaling and suggest that targeting this pathway could sensitize drug-resistant cells to chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 1×
“are both resistant to a wide range of chemotherapies [15–19].”
BackgroundProtein translation and folding are coupled by an endoplasmic-reticulum-resident kinase
Harding, H. P., Zhang, Y., & Ron, D. (1999) · Nature · doi:10.1038/16729 · Cited by 3,310 · cited 1×
“In particular, Nrf2 is directly phosphorylated and activated by the ER-membrane kinase PERK, which is canonically activated under conditions of ER stress as part of the unfolded protein response (UPR) [40–42].”
BackgroundAssociation of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545 · cited 1×
“are both resistant to a wide range of chemotherapies [15–19].”
BackgroundHeme oxygenase: Function, multiplicity, regulatory mechanisms, and clinical applications
Maines, M. D. (1988) · The FASEB Journal · doi:10.1096/fasebj.2.10.3290025 · Cited by 1,707 · cited 1×
“HMOX-1 is a well-characterized enzyme involved in the metabolism of heme, but is also a major target of master antioxidant regulator Nrf2 [29–31].”
BackgroundStochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
Gupta, P. B., Fillmore, C. M., Jiang, G., Shapira, S. D., Tao, K., Kuperwasser, C., & Lander, E. S. (2011) · Cell · doi:10.1016/j.cell.2011.07.026 · Cited by 1,475
Self-citationMolecular mechanisms of N-acetylcysteine actions
Zafarullah, M., Li, W. Q., Sylvester, J., & Ahmad, M. (2003) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s000180300001 · Cited by 1,343 · cited 1×
“Treatment with a ROS-scavenging agent n-acetyl cysteine (NAC) was able to rescue this decreased survival, indicating that PERK pathway activation contributes to chemotherapy resistance in significant part via ROS buffering (Figure 4c,d) [46].”
BackgroundRamos-Gomez, M., Kwak, M.-K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., & Kensler, T. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051618798 · Cited by 1,102
Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060 · cited 1×
“This finding is of particular interest given Nrf2’s known role in promoting chemotherapy survival [34] and its constitutive activation by mutation in a subset of tumors [52–54].”
Background
Cited by
UPR, autophagy, and mitochondria crosstalk underlies the ER stress response
Senft, D., & Ronai, Z. A. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.01.002 · Cited by 1,121
Proteostasis control by the unfolded protein response
Hetz, C., Chevet, E., & Oakes, S. A. (2015) · Nature Cell Biology · doi:10.1038/ncb3184 · Cited by 748
Endoplasmic Reticulum Stress and the Hallmarks of Cancer
Urra, H., Dufey, E., Avril, T., Chevet, E., & Hetz, C. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.03.007 · Cited by 615
Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance
Gupta, P. B., Pastushenko, I., Skibinski, A., Blanpain, C., & Kuperwasser, C. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.11.011 · Cited by 598
Self-citationEndoplasmic Reticulum Stress–Activated Cell Reprogramming in Oncogenesis
Chevet, E., Hetz, C., & Samali, A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1490 · Cited by 380
Protein kinase R-like ER kinase and its role in endoplasmic reticulum stress-decided cell fate
Liu, Z., Lv, Y., Zhao, N., Guan, G., & Wang, J. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.183 · Cited by 313
Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers
Avril, T., Vauléon, E., & Chevet, E. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.72 · Cited by 277
Roles of Nrf2 in cell proliferation and differentiation
Murakami, S., & Motohashi, H. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.030 · Cited by 225
Type I interferons and endoplasmic reticulum stress in health and disease
(2020) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.10.004 · Cited by 83
Involvement of NRF2 in Breast Cancer and Possible Therapeutical Role of Polyphenols and Melatonin
Tascioglu Aliyev, A., Panieri, E., Stepanić, V., Gurer-Orhan, H., & Saso, L. (2021) · Molecules · doi:10.3390/molecules26071853 · Cited by 50
“tried to elucidate the role of NRF2 in the acquisition of multidrug resistance (MDR) caused by cellular dedifferentiation by comparing normally differentiated or dedifferentiated isogenic human breast epithelial cells by the induction of epithelial-to-mesenchymal transition (EMT) due to the expression of the transcrip…”
BackgroundNrf2/P–glycoprotein axis is associated with clinicopathological characteristics in colorectal cancer
Sadeghi, M. R., Jeddi, F., Soozangar, N., Somi, M. H., Shirmohamadi, M., Khaze, V., & Samadi, N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.062 · Cited by 44
Endoplasmic Reticulum Stress and Tumor Microenvironment in Bladder Cancer: The Missing Link
Nie, Z., Chen, M., Wen, X., Gao, Y., Huang, D., Cao, H., Peng, Y., Guo, N., Ni, J., & Zhang, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.683940 · Cited by 43
“As a rationale, the inhibition of PERK signaling reversed the multidrug resistance of de-differentiated breast cancer cells (Del Vecchio et al., 2014), and the inhibition of the eIF2αdependent arm of UPR reversed the tumor radioresistance in a subset of hypoxic glioblastoma cells (Rouschop et …”
Background
Metadata
- Authors
- Del Vecchio, C. A., Feng, Y., Sokol, E. S., Tillman, E. J., Sanduja, S., Reinhardt, F., & Gupta, P. B.
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-09-09
- Volume
- 12
- Issue
- 9
- Pages
- e1001945
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- OpenAlex
- W2003714060
- Cited by
- 116
- References
- 13
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.